

Results of General Meeting

Neurotech International Limited (ASX: NTI) ("Neurotech" or "the Company") today held a General Meeting of Members at the offices of BDO Australia - Melbourne, Collins Square, Tower 4, Level 18, 727 Collins St, Docklands VIC 3008.

All resolutions were determined by a poll.

The outcome of each resolution put to shareholders at the General Meeting is set out in the Annexure which accompanies this release.

Authority

This announcement has been authorised for release by Alessandra Gauvin, Joint Company Secretary.

Investors:

Dr Thomas Duthy

Executive Director

td@neurotechinternational.com

+61 (0)402 493 727

About Neurotech

Neurotech International Limited (ASX:NTI) is a clinical-stage biopharmaceutical development company focused predominately on paediatric neurological disorders with a broad-spectrum oral cannabinoid drug therapy called NTI164. Neurotech has completed a Phase II/III randomised, double-blind, placebo-controlled clinical trial in Autism Spectrum Disorder (ASD) with clinically meaningful and statistically significant benefits reported across a number of clinically-validated measures and excellent safety. In addition, Neurotech has completed and reported statistically significant and clinically meaningful Phase I/II trials in ASD and Paediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Infections (PANDAS) and Paediatric Acute-Onset Neuropsychiatric Syndrome (PANS), collectively PANDAS/PANS along with Rett Syndrome. Neurotech has received human ethics committee clearance for a Phase I/II clinical trial in spastic cerebral palsy.

For more information about Neurotech please visit <http://www.neurotechinternational.com>.

Disclosure of Proxy Votes

Neurotech International Limited

General Meeting

Tuesday, 10 September 2024



GPO Box 5193, Sydney, NSW 2001
P 1300 288 664 (aus) or +61 (0)2 9698 5414 (world)
F +61 (0)2 8583 3040 E hello@automic.com.au
ABN 27 152 260 814

In accordance with section 251AA of the Corporations Act 2001, the following information is provided in relation to resolutions put to members at the meeting.

			Proxy Votes				Poll Results (if applicable)			Results
Resolution	Decided by Show of Hands (S) or Poll (P)	Total Number of Proxy Votes exercisable by proxies validly appointed	FOR	AGAINST	ABSTAIN	PROXY'S DISCRETION	FOR	AGAINST	ABSTAIN	OUTCOME
1 ISSUE OF OPTIONS TO RELATED PARTY – ROBERT MAXWELL JOHNSTON	P	71,988,037	32,823,403 45.60%	2,304,499 3.20%	170,000	36,860,135 51.20%	69,817,082 96.80%	2,304,499 3.20%	170,000	Passed
2 APPROVAL TO ISSUE SHARES AND PERFORMANCE RIGHTS TO FENIX	P	72,003,037	34,034,123 47.27%	1,108,779 1.54%	155,000	36,860,135 51.19%	71,367,802 98.47%	1,108,779 1.53%	155,000	Passed
3 RATIFICATION OF PRIOR ISSUE OF SHARES AND OPTIONS UNDER PLACEMENT – LISTING RULE 7.1	P	70,003,747	32,242,833 46.06%	900,779 1.29%	960,139	36,860,135 52.65%	69,576,512 98.72%	900,779 1.28%	960,139	Passed
4 RATIFICATION OF PRIOR ISSUE OF SHARES UNDER PLACEMENT – LISTING RULE 7.1A	P	70,885,846	33,110,982 46.71%	914,729 1.29%	78,040	36,860,135 52.00%	70,444,661 98.72%	914,729 1.28%	78,040	Passed
5 APPROVAL TO VARY TERMS OF OPTIONS ON ISSUE TO THOMAS DUTHY	P	71,988,037	32,859,765 45.65%	2,268,137 3.15%	170,000	36,860,135 51.20%	69,853,444 96.86%	2,268,137 3.14%	170,000	Passed

